Vertex Pharmaceuticals | Les Charges D'Exploitation



Operating Expenses Changement Date
AbbVie USD 16.59B 5.96B 2024-12
Acadia Pharmaceuticals USD 106.1M 112.66M 2024-12
Agios Pharmaceuticals USD 135.77M 1.11B 2024-12
Alnylam Pharmaceuticals USD 698.32M 120.5M 2024-12
Amgen USD 6.78B 401M 2024-12
Arrowhead Research USD 163.91M 1.71M 2024-12
Biogen USD 2.01B 13.3M 2024-12
BioMarin Pharmaceutical USD 585.91M 45.94M 2024-12
Bristol-Myers Squibb USD 11.55B 1.84B 2024-12
Gilead Sciences USD 5.12B 1.54B 2024-12
Incyte USD 877.18M 114.6M 2024-12
Insmed USD 334.86M 28M 2024-12
Ionis Pharmaceuticals USD 337.4M 54.93M 2024-12
J&J USD 18.63B 500M 2024-12
Merck USD 11.33B 1.4B 2024-12
Moderna USD 2.21B 280M 2024-12
Neurocrine Biosciences USD 485.7M 47.4M 2024-12
Novartis USD 11.28B 1.73B 2024-12
Pfizer USD 18.17B 5.63B 2024-12
PTC Therapeutics USD 275.66M 24.36M 2024-12
Regeneron Pharmaceuticals USD 2.8B 26.53B 2024-12
Roche Holding CHF 11.43B 1.48B 2024-12
Sanofi EUR 10.07B 969M 2024-09
Sarepta Therapeutics USD 496.73M 51.76M 2024-12
Ultragenyx Pharmaceutical USD 287.15M 15.67M 2024-12
United Therapeutics USD 378.2M 27.6M 2024-12
Vertex Pharmaceuticals USD 1.89B 230.4M 2024-12



Vertex Pharmaceuticals Les Charges D'Exploitation - Les valeurs actuelles, des données historiques, des prévisions, des statistiques, des tableaux et le calendrier économique - Mar 2025.